News Feed Opinion Blog Posts Career Updates Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
September, 2025
September 2025
M T W T F S S
1234567
891011121314
15161718192021
22232425262728
2930  
Matthias Guckenberger: SANO Trial – Non-Surgical Approach in Esophageal Cancer with Complete Response
Matthias Guckenberger/X
Apr 16, 2025, 10:15

Matthias Guckenberger: SANO Trial – Non-Surgical Approach in Esophageal Cancer with Complete Response

Matthias Guckenberger, Chairman at University Hospital Zurich, shared on X:

“SANO trial: non-surgical approach and organ preservation in patients esophageal cancer and complete clinical response after neoadjuvant RCT

Virtual Grand Rounds in Radiation Oncology

Wednesday May 7th 17:00 – 17:30 – Safe the date!”

Matthias Guckenberger

cancer esophageal cancer Matthias Guckenberger OncoDaily Oncology RCT SANO trial
Special Coverage
Voices
Sep 7, 2025, 15:24
Katie Coleman: “What Do Patients Want” is a Moving Target
Insight
Sep 7, 2025, 15:17
Udhayvir Grewal: Palliative Care and End-of-Life Care in Esophageal Cancer
Voices
Sep 7, 2025, 14:57
Zeynep Ozay: Learning and Growing at Huntsman Cancer Institute
Insight
Sep 7, 2025, 14:57
Gerry Hanna Spotlights Editorial on Reframing Radiotherapy in Radiation Oncology
Voices
Sep 7, 2025, 14:41
Roberto Borea: My Very First WCLC 2025 as an IASLC Academy Member
Insight
Sep 7, 2025, 14:29
R. Bryan Rumble: ASCO Guideline Clinical Insights - Systemic therapy in mCRPC
Voices
Sep 7, 2025, 14:23
Body Speaks, Listen - Acute Leukemia Advocates Network
Voices
Sep 7, 2025, 14:05
Top 10 Oncogrants of the Week: Advancing Breakthroughs in Cancer Care
Voices
Sep 7, 2025, 13:56
Sumanta K. Pal: Terrific Talk by Laurence Albiges on Biomarkers in Kidney Cancer at IUCS25
Career Updates
Sep 7, 2025, 13:47
Solange Peters Honored with the IASLC Paul A. Bunn, Jr. Scientific Award 2025
Blog Posts
Sep 7, 2025, 13:37
World Radiotherapy Awareness Day, September 7: Recognizing the Hidden Hero of Cancer Care
New Paper Alert
Sep 7, 2025, 13:22
Amivantamab–Lazertinib Improves Survival Over Osimertinib in EGFR-Mutated NSCLC